Core Viewpoint - Vison Pharma-B (02561) has seen a significant stock price increase, currently trading at 44.68 HKD, reflecting a rise of 2.81% [1] Group 1: Company Developments - The fastest R&D progress for Vison Pharma is with Long-acting Growth Hormone, expected to be approved for domestic market launch in the second half of 2025, potentially becoming the third long-acting growth hormone available in China [1] - The company has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] - In June, Vison Pharma partnered with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, Vison Pharma collaborated with Anke Bio (300009) to jointly promote product commercialization, indicating promising future market prospects [1]
维昇药业-B再涨近4% 隆培促生长素有望年内获批上市 公司持续推进商业化进程